论文部分内容阅读
绿脓杆菌感染,在临床治疗中是一个比较困难的问題。近两年生产的一种半合成抗菌素——呋喃酰脲苄青霉素(简称呋苄青霉素),在我国已有临床应用。它虽然也是一种广谱抗菌素,但在临床上主要用于绿脓杆菌感染。它的疗效强于近几年较普遍应用的羧苄青霉素(其作用约比羧苄青霉素强8～16倍),其毒性明显低于多粘菌素B和多粘菌素E。目前,呋苄青霉素是比较理想的抗绿脓杆菌药物,现将该药简单介绍如下:
Pseudomonas aeruginosa infection, in clinical treatment is a more difficult issue. The past two years, the production of a semi-synthetic antibiotic - furanyl carbenicillin (referred to as furica penicillin), has been in clinical application. Although it is also a broad-spectrum antibiotic, it is mainly used clinically for Pseudomonas aeruginosa infection. Its efficacy is stronger than the more commonly used carbenicillin in recent years (its role is about 8 to 16 times stronger than carbenicillin), its toxicity was significantly lower than polymyxin B and polymyxin E. Currently, furicillin is an ideal anti-Pseudomonas aeruginosa drugs, the drug is now briefly described as follows: